Varian Medical Systems, Inc. (VAR): Price and Financial Metrics

Varian Medical Systems, Inc. (VAR)

Today's Latest Price: $172.86 USD

0.64 (-0.37%)

Updated Sep 18 7:00pm

Add VAR to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 138 in Medical - Devices & Equipment

See all "A" rated Strong Buy stocks

VAR Stock Summary

  • Varian Medical Systems Inc's market capitalization of $15,720,085,115 is ahead of 89% of US-listed equities.
  • VAR's went public 32.73 years ago, making it older than 89.34% of listed US stocks we're tracking.
  • The price/operating cash flow metric for Varian Medical Systems Inc is higher than 92.75% of stocks in our set with a positive cash flow.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Varian Medical Systems Inc are ATHM, ZBRA, DOX, ENTG, and BILI.
  • Visit VAR's SEC page to see the company's official filings. To visit the company's web site, go to
VAR Daily Price Range
VAR 52-Week Price Range

VAR Stock Price Chart Technical Analysis Charts

VAR Price/Volume Stats

Current price $172.86 52-week high $176.19
Prev. close $173.50 52-week low $89.62
Day low $172.62 Volume 2,341,882
Day high $173.63 Avg. volume 1,029,290
50-day MA $159.20 Dividend yield N/A
200-day MA $134.26 Market Cap 15.72B

Varian Medical Systems, Inc. (VAR) Company Bio

Varian Medical Systems designs, manufactures, sells, and services medical devices and software products for treating cancer and other medical conditions in the United States. The company operates in two segments, Oncology Systems and Imaging Components. The company was founded in 1948 and is based in Palo Alto, California.

VAR Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$172.86$18.15 -90%

We started the process of determining a valid price forecast for Varian Medical Systems Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Varian Medical Systems Inc ranked in the 11th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. The most interesting components of our discounted cash flow analysis for Varian Medical Systems Inc ended up being:

  • Its compound free cash flow growth rate, as measured over the past 5.72 years, is -0.05% -- higher than just 18.58% of stocks in our DCF forecasting set.
  • VAR's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 45.61% of tickers in our DCF set.
  • Relative to other stocks in its sector (Healthcare), Varian Medical Systems Inc has a reliance on debt greater than just 24.66% of them.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as VAR, try LGND, STAA, PCRX, DYNT, and RGEN.

VAR Latest News Stream

Event/Time News Detail
Loading, please wait...

VAR Latest Social Stream

Loading social stream, please wait...

View Full VAR Social Stream

Latest VAR News From Around the Web

Below are the latest news stories about Varian Medical Systems Inc that investors may wish to consider to help them evaluate VAR as an investment opportunity.

Bragar Eagel & Squire, P.C. Reminds Investors that it is Investigating the Boards of Directors of Rosetta Stone, Momenta, Jernigan, and Varian on behalf of Stockholders and Encourages Investors to Contact the Firm

NEW YORK, Sept. 16, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C. reminds investors that it is investigating potential claims on behalf of stockholders of Rosetta Stone Inc. (NYSE: RST), Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), Jernigan Capital, Inc. (NYSE: JCAP), and Varian Medical Systems, Inc. (NYSE: VAR).  Additional information about each potential action can be found at the link provided. Rosetta Stone Inc. (NYSE: RST)Buyer: Cambium Learning GroupOn August 31, 2020, Rosetta Stone announced that it had signed an agreement to be acquired by Cambium for approximately $792 million.  Pursuant to the merger agreement, Rosetta Stone stockholders will receive $30 in cash for each share of Rosetta Stone common stock owned.  The deal is scheduled to close in the fourth quarter ...

Yahoo | September 16, 2020

Lifshitz Law Firm, P.C. Announces Investigation of Immunomedics, Inc. (NASDAQ: IMMU), Livongo Health, Inc. (NASDAQ:LVGO), Varian Medical Systems, Inc. (NYSE: VAR) and Virtusa Corporation (NASDAQ: VRTU)

NEW YORK, Sept. 16, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU)Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of Immunomedics to Gilead Sciences, Inc. for $88.00 per share in cash. If you are a IMMU investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected] Livongo Health, Inc. (NASDAQ:LVGO)Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of LVGO to Teladoc Health, Inc. for 0.5920x Teladoc shares plus cash consideration of $11.33 per share. If you are a LVGO investor, and would li...

Yahoo | September 16, 2020

SHAREHOLDER ALERT: Monteverde & Associates Reminds Investors of its Ongoing Investigation Regarding the Merger

NEW YORK, NY / ACCESSWIRE / September 16, 2020 / Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating: * National General Holdings Corp.

Yahoo | September 16, 2020

Varian Expects to Benefit from the Extension of Medical Linear Accelerators Tariff Exclusion in China

Varian (NYSE: VAR) has received notice from the Customs Tariff Commission of the State Council of China that the first exclusion of the additional tariffs China imposed on US products will expire on September 16, 2020. In accordance with procedures, the exclusion will be extended by one year, from September 17, 2020 to September 16, 2021. Varian medical linear accelerators are one of the first items to be excluded from additional tariffs.

Yahoo | September 16, 2020

Lifshitz Law Firm, P.C. Announces Investigation of Cellular Biomedicine Group, Inc. (NASDAQ: CBMG), GCI Liberty, Inc. (NASDAQ: GLIBA), Maxim Integrated Products (NASDAQ:MXIM), National General Holdings Corp. (NASDAQ: NGHC), Pfenex Inc. (NYSE: PFNX), Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH), and Varian Medical Systems, Inc. (NYSE: VAR)

Cellular Biomedicine Group, Inc. (NASDAQ: CBMG)

Yahoo | September 15, 2020

Read More 'VAR' Stories Here

VAR Price Returns

1-mo 0.21%
3-mo 45.63%
6-mo 68.94%
1-year 47.08%
3-year 65.21%
5-year 123.77%
YTD 21.72%
2019 25.33%
2018 1.94%
2017 23.80%
2016 11.11%
2015 -6.60%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8267 seconds.